Education
About Us
Working with TipRanks
Follow Us
Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
Top Page
Scinai Immunotherapeutics
(NASDAQ:SCNI)
Select Model
Select Model
Rating:52Neutral
Price Target:―
Scinai Immunotherapeutics is undergoing a financial recovery but faces significant challenges such as negative cash flows and high debt levels. The stock shows neutral technical indicators, suggesting moderate market confidence. Its attractive valuation might appeal to value investors, but the absence of dividends and financial risks may deter more conservative investors.
Scinai Immunotherapeutics (SCNI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.02M
Dividend YieldN/A
Average Volume (3M)142.27K
Price to Earnings (P/E)0.3
Beta (1Y)1.25
Revenue Growth306.41%
EPS GrowthN/A
CountryUS
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.72
Shares Outstanding933,679
10 Day Avg. Volume87,442
30 Day Avg. Volume142,267
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.00
Price to Sales (P/S)4.11
P/FCF Ratio0.00
Enterprise Value/Market Cap8.40
Enterprise Value/Revenue7.49
Enterprise Value/Gross Profit-5.10
Enterprise Value/Ebitda1.03
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Scinai Immunotherapeutics Business Overview & Revenue Model
Company DescriptionScinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
How the Company Makes MoneyScinai Immunotherapeutics generates revenue primarily through the development and commercialization of its immunotherapeutic products. The company earns money by progressing its drug candidates through clinical trials, obtaining regulatory approvals, and subsequently launching these products in the market. Revenue streams include product sales, licensing agreements, and strategic partnerships with other pharmaceutical or biotechnology companies. These partnerships often involve milestone payments and royalties related to the development and commercialization of SCNI's proprietary technologies. Additionally, the company may receive funding through grants and collaborations aimed at advancing its research and development efforts.
Scinai Immunotherapeutics Earnings Call Summary
Earnings Call Date:Aug 21, 2025
(Q2-2024)
| % Change Since: |
Next Earnings Date:Nov 26, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive and negative aspects. While there were notable achievements such as the reduction in net loss, positive regulatory feedback, and growth in the CDMO business, there were also challenges like a significant decrease in cash position and negative shareholder equity. The sentiment is balanced with both opportunities and financial restructuring challenges.Q2-2024 Updates
Positive Updates
Reduction in Operating Expenses
R&D expenses decreased to $2.79 million compared to $3.45 million the previous year, and marketing and G&A expenses were reduced to $1 million from $2.3 million the previous year.
Net Loss Reduction
Net loss for the first 6 months of 2024 was reduced to $4.48 million compared to $7.28 million in the first 6 months of 2023.
Positive Regulatory Feedback
Received positive regulatory feedback from the Paul Erlich Institute for their drug development program towards Phase I/IIa clinical trial of their anti-IL-17 AF nanoAb in plaque psoriasis.
CDMO Business Growth
CDMO unit generated work orders valued at $600,000 from 5 clients since January 2024 with a 2024 guidance of $1.25 million.
Private Equity Commitment
Received a $2 million equity commitment from Daniel Stone through RK Stone Miami LLC, with the commitment valid until December 31, 2024.
Negative Updates
Cash Position Decrease
Cash available as of June 30, 2024, was $3.21 million, down from $7.63 million at the end of June 30, 2023.
Negative Shareholder Equity
Shareholder equity was negative $7.28 million compared to negative $4.57 million as of June 30, 2023.
EIB Loan Restructuring Required
The EIB loan restructuring deal was necessary to convert a large debt into equity, highlighting financial restructuring needs.
Company Guidance
In the Q2 2024 earnings call for Scinai Immunotherapeutics, CEO Amir Reichman provided detailed guidance on the company's strategic objectives and financial outlook. Scinai aims to fast-track IL-17 development to toxicology studies and increase CDMO business unit sales to $1.25 million. The company plans to reduce R&D risks by partnering with other pharma companies while maintaining careful spending to control its burn rate. Financially, Scinai reported a net loss of $4.48 million for the first half of 2024, a decrease from $7.28 million in the same period in 2023, attributed to reduced operating expenses. In addition, Scinai is working on a debt-to-equity restructuring deal expected to positively impact shareholder equity by approximately $19 million. The company also announced a $2 million equity commitment from Daniel Stone, which will provide additional financial flexibility. Overall, the guidance highlights Scinai's focus on advancing its R&D pipeline and CDMO business while ensuring financial stability and growth.Scinai Immunotherapeutics Financial Statement Overview
Summary
Scinai Immunotherapeutics shows some signs of financial recovery with positive net income in the TTM period. However, it faces significant challenges, including negative cash flows, high debt levels, and negative margins, which could impact its sustainability and growth prospects. Continued focus on revenue generation and cost management will be crucial for future stability.Income Statement
The company has shown some improvement in net income, transitioning from negative to positive figures in the TTM period. However, the gross profit margin is negative, indicating that the cost of goods sold is higher than the revenue. Additionally, the EBIT and EBITDA margins are inconsistent, with a significantly negative EBITDA margin in TTM, pointing to high operational costs. The revenue growth rate is not applicable due to zero revenue in previous periods.40
Negative
Balance Sheet
The balance sheet shows a relatively strong equity position in the TTM period with positive stockholders' equity compared to previous negative figures. However, the debt-to-equity ratio is high due to significant total debt, indicating potential financial risk. The equity ratio has improved but remains at risk given the industry context.35
Negative
Cash Flow
The cash flow statement indicates a challenging situation with negative operating cash flow and free cash flow in the TTM period, though there is an improvement compared to previous periods. Free cash flow to net income ratio shows a concerning trend as free cash flow remains negative. The company is not generating sufficient cash to cover its operational activities.45
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.15M | 658.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.69M | -580.00K | -512.67K | -559.80K | -747.65K | -708.92K |
| EBITDA | 8.35M | 7.87M | -9.19M | -10.50M | -10.39M | 2.75M |
| Net Income | 4.61M | 4.80M | -6.50M | -5.80M | -8.21M | -1.39M |
Balance Sheet | ||||||
| Total Assets | 11.84M | 13.45M | 17.47M | 27.07M | 32.04M | 17.71M |
| Cash, Cash Equivalents and Short-Term Investments | 989.00K | 1.96M | 4.87M | 14.07M | 17.37M | 2.93M |
| Total Debt | 2.36M | 2.09M | 20.56M | 21.54M | 28.98M | 20.90M |
| Total Liabilities | 3.98M | 3.47M | 22.04M | 28.83M | 31.05M | 22.25M |
| Stockholders Equity | 7.86M | 9.98M | -4.57M | -1.76M | 982.00K | -4.54M |
Cash Flow | ||||||
| Free Cash Flow | -5.71M | -6.35M | -10.02M | -8.10M | -7.57M | -24.48M |
| Operating Cash Flow | -5.69M | -6.33M | -9.38M | -7.26M | -7.43M | -22.57M |
| Investing Cash Flow | -16.00K | -12.00K | -637.00K | -836.00K | -139.00K | -1.85M |
| Financing Cash Flow | 3.59M | 3.44M | 1.09M | 6.78M | 21.43M | 4.27M |
Scinai Immunotherapeutics Technical Analysis
Negative
1.39
Price Trends
1.58
Negative
2.02
Negative
2.59
Negative
Market Momentum
-0.09
Positive
44.62
Neutral
21.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNI, the sentiment is Negative. The current price of 1.39 is below the 20-day moving average (MA) of 1.47, below the 50-day MA of 1.58, and below the 200-day MA of 2.59, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 44.62 is Neutral, neither overbought nor oversold. The STOCH value of 21.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCNI.
Scinai Immunotherapeutics Risk Analysis
Scinai Immunotherapeutics disclosed 78 risk factors in its most recent earnings report. Scinai Immunotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scinai Immunotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $53.85M | -0.43 | 41.08% | ― | -5.77% | -22.78% | |
52 Neutral | $1.02M | 0.26 | 138.38% | ― | 306.41% | ― | |
50 Neutral | $144.16M | -0.86 | -58.44% | ― | -31.23% | 14.92% | |
48 Neutral | $107.45M | -2.96 | -78.08% | ― | 303.47% | 73.70% | |
48 Neutral | $1.09B | -12.87 | -15.91% | ― | 83.36% | 22.27% | |
41 Neutral | $32.10M | -0.18 | 239.23% | ― | -53.61% | -93.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SCNI
Scinai Immunotherapeutics
1.39
-2.32
-62.53%
QCLS
Q/C Technologies
―
―
―
ENTO
Entero Therapeutics
4.29
3.25
312.50%
PTIX
Protagenic Therapeutics
3.38
-5.52
-62.02%
ZVSA
ZyVersa Therapeutics
0.14
-2.12
-93.81%
ELAB
PMGC Holdings
5.17
-641.63
-99.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.